Aslan Pharmaceuticals Stock Working Capital
Aslan Pharmaceuticals fundamentals help investors to digest information that contributes to Aslan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aslan Stock. The fundamental analysis module provides a way to measure Aslan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aslan Pharmaceuticals stock.
Aslan |
Aslan Pharmaceuticals Company Working Capital Analysis
Aslan Pharmaceuticals' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Aslan Pharmaceuticals Working Capital | 11.02 M |
Most of Aslan Pharmaceuticals' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aslan Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Aslan Pharmaceuticals has a Working Capital of 11.02 M. This is 97.41% lower than that of the Biotechnology sector and 97.95% lower than that of the Health Care industry. The working capital for all United States stocks is 99.25% higher than that of the company.
Aslan Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aslan Pharmaceuticals' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics of similar companies.Aslan Pharmaceuticals is currently under evaluation in working capital category among its peers.
Aslan Fundamentals
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 288.33 M | |||
| Shares Outstanding | 2.83 M | |||
| Shares Owned By Insiders | 0.14 % | |||
| Shares Owned By Institutions | 13.21 % | |||
| Number Of Shares Shorted | 306.56 K | |||
| Price To Earning | (11.50) X | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 0.94 X | |||
| Revenue | 12 M | |||
| Gross Profit | 79.82 M | |||
| EBITDA | (43.39 M) | |||
| Net Income | (44.22 M) | |||
| Cash And Equivalents | 78.12 M | |||
| Cash Per Share | 1.12 X | |||
| Total Debt | 26.83 M | |||
| Debt To Equity | 1.12 % | |||
| Current Ratio | 6.97 X | |||
| Book Value Per Share | (7.70) X | |||
| Cash Flow From Operations | (46.36 M) | |||
| Short Ratio | 1.85 X | |||
| Earnings Per Share | (16.00) X | |||
| Target Price | 72.0 | |||
| Number Of Employees | 35 | |||
| Beta | 1.4 | |||
| Market Capitalization | 1.7 M | |||
| Total Asset | 24.63 M | |||
| Retained Earnings | (321.07 M) | |||
| Working Capital | 11.02 M | |||
| Current Asset | 54.61 M | |||
| Current Liabilities | 5.15 M | |||
| Net Asset | 24.63 M |
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Stanley Black could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Stanley Black when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Stanley Black - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Stanley Black Decker to buy it.
The correlation of Stanley Black is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Stanley Black moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Stanley Black Decker moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Stanley Black can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |